These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 21095048)

  • 1. JAK2 inhibitors: what's the true therapeutic potential?
    Santos FP; Verstovsek S
    Blood Rev; 2011 Mar; 25(2):53-63. PubMed ID: 21095048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.
    Quintás-Cardama A; Verstovsek S
    Cancer; 2012 Feb; 118(4):870-7. PubMed ID: 21766300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors.
    Helbig G
    Med Oncol; 2018 Aug; 35(9):119. PubMed ID: 30074114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potential of JAK2 inhibitors.
    Verstovsek S
    Hematology Am Soc Hematol Educ Program; 2009; ():636-42. PubMed ID: 20008249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New JAK2 inhibitors for myeloproliferative neoplasms.
    Quintás-Cardama A; Verstovsek S
    Expert Opin Investig Drugs; 2011 Jul; 20(7):961-72. PubMed ID: 21521147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?
    Tibes R; Mesa RA
    Leuk Lymphoma; 2011 Jul; 52(7):1178-87. PubMed ID: 21599574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.
    Payzin KB; Savasoglu K; Alacacioglu I; Ozdemirkiran F; Mutlu BB; Bener S; Calli AO; Kucukzeybek BB; Aksun S
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):525-33. PubMed ID: 24811089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental therapeutics for patients with myeloproliferative neoplasias.
    Agrawal M; Garg RJ; Cortes J; Kantarjian H; Verstovsek S; Quintas-Cardama A
    Cancer; 2011 Feb; 117(4):662-76. PubMed ID: 20922795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Risk Janus Kinase 2 V617F Allele Burden in a Seven-Year Cohort of Patients with Myeloproliferative Neoplasms.
    Chatambudza M; Skhosana L; Ketseoglou I; Wiggill T
    Clin Lab; 2021 Nov; 67(11):. PubMed ID: 34758219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies.
    Passamonti F; Maffioli M; Caramazza D; Cazzola M
    Oncotarget; 2011 Jun; 2(6):485-90. PubMed ID: 21646683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
    Duletić AN; Dekanić A; Hadzisejdić I; Kusen I; Matusan-Ilijas K; Grohovac D; Grahovac B; Jonjić N
    Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
    Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK2 inhibitors: are they the solution?
    Santos FP; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1(0 1):S28-36. PubMed ID: 22035745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
    Treliński J; Robak T
    Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors.
    Randhawa J; Ostojic A; Vrhovac R; Atallah E; Verstovsek S
    J Hematol Oncol; 2012 Aug; 5():43. PubMed ID: 22852872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.
    Berdeja J; Palandri F; Baer MR; Quick D; Kiladjian JJ; Martinelli G; Verma A; Hamid O; Walgren R; Pitou C; Li PL; Gerds AT
    Leuk Res; 2018 Aug; 71():82-88. PubMed ID: 30025280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical Analysis of Driver Mutations in Patients with Ph Negative Myeloproliferative Neoplasms].
    He ZP; Tian HY; Tan M; Wu Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):842-848. PubMed ID: 29950230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Myeloproliferative diseases caused by JAK2 mutation].
    Nagata K; Shimoda K
    Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
    Labastida-Mercado N; Galindo-Becerra S; Garcés-Eisele J; Colunga-Pedraza P; Guzman-Olvera V; Reyes-Nuñez V; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
    Hematol Oncol Stem Cell Ther; 2015 Mar; 8(1):16-21. PubMed ID: 25637689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.